DocSym
β
Searchsearch
Search
(G13.2*) Systemic atrophy primarily affecting central nervous system in myxoedema
More details coming soon
NaN% mortality rate associated with the disease systemic atrophy primarily affecting central nervous system in myxoedema
Diagnosis systemic atrophy primarily affecting central nervous system in myxoedema is diagnosed Prevalent in Women Only
0
Men receive the diagnosis systemic atrophy primarily affecting central nervous system in myxoedema
0 (No mortality)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
0
Women receive the diagnosis systemic atrophy primarily affecting central nervous system in myxoedema
0 (No mortality)Died from this diagnosis.
Risk Group for the Disease systemic atrophy primarily affecting central nervous system in myxoedema - Men and Women aged 0
No Cases of the Disease Systemic atrophy primarily affecting central nervous system in myxoedema identified in Men
Less common in men the disease occurs at Age 0-95+Less common in women the disease occurs at Age 0-95+
No Cases of the Disease Systemic atrophy primarily affecting central nervous system in myxoedema identified in Men
Disease Features systemic atrophy primarily affecting central nervous system in myxoedema
Absence or low individual and public risk
Systemic atrophy primarily affecting central nervous system in myxoedema - what does this mean
Systemic atrophy primarily affecting central nervous system in myxoedema is a rare disorder that is caused by a deficiency of thyroid hormones, leading to a decrease in the activity of the nervous system. this results in a decrease in the size of the nerve cells and the destruction of the myelin sheath, which is the protective covering of the nerve cells. this can lead to a variety of neurological symptoms, such as muscle weakness, difficulty walking, and impaired cognitive function.
What happens during the disease - systemic atrophy primarily affecting central nervous system in myxoedema
Systemic atrophy primarily affecting the central nervous system in myxoedema is caused by a decrease in the production of thyroid hormones. this decrease in hormones leads to decreased metabolic activity in the cells of the central nervous system, resulting in the death of these cells and the subsequent atrophy of the affected area. this can cause a wide range of symptoms, including memory loss, confusion, difficulty speaking, and other neurological deficits.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Medical History and Physical Examination
- Blood Tests
- Spinal Fluid Analysis
- Brain Imaging Studies
- Electroencephalogram (EEG)
- Nerve Conduction Studies
- Electromyography (EMG)
- Muscle Biopsy
Treatment and Medical Assistance
Main goal of the treatment: To reduce the symptoms of myxoedema and systemic atrophy.
- Administering thyroid hormone replacement therapy.
- Prescribing medications to reduce inflammation.
- Prescribing medications to reduce muscle spasms.
- Prescribing medications to reduce fatigue.
- Prescribing medications to reduce pain.
- Prescribing medications to improve circulation.
- Prescribing medications to improve cognitive function.
- Providing physical therapy to improve mobility.
- Providing occupational therapy to improve daily activities.
- Providing speech and language therapy to improve communication.
- Providing counseling and support to reduce stress.
- Providing nutritional advice to improve overall health.
No Hospitalization Required
Average Time for Outpatient Care Not Established
Systemic atrophy primarily affecting central nervous system in myxoedema - Prevention
Myxoedema is a systemic atrophy primarily affecting the central nervous system. prevention of this condition can be achieved by early diagnosis and prompt treatment of hypothyroidism, which is the underlying cause of myxoedema. additionally, maintaining an adequate nutritional intake, good hydration, and an active lifestyle can help prevent the onset of myxoedema.